Edition:
United States

ALK-Abello A/S (ALKb.CO)

ALKb.CO on Copenhagen Stock Exchange

991.50DKK
24 May 2017
Change (% chg)

kr.1.50 (+0.15%)
Prev Close
kr.990.00
Open
kr.989.00
Day's High
kr.997.00
Day's Low
kr.989.00
Volume
5,924
Avg. Vol
12,865
52-wk High
kr.1,267.00
52-wk Low
kr.839.00

ALKb.CO

Chart for ALKb.CO

About

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The... (more)

Overall

Beta: 0.72
Market Cap(Mil.): kr.9,129.33
Shares Outstanding(Mil.): 9.21
Dividend: 5.00
Yield (%): 0.50

Financials

  ALKb.CO Industry Sector
P/E (TTM): 67.00 14.35 17.42
EPS (TTM): 14.80 -- --
ROI: 4.02 -7.29 -5.45
ROE: 5.34 -6.80 -4.73

BRIEF-ALK-Abello Q1 EBITDA DKK 140 million

* Q1 TOTAL REVENUE DKK 789 MILLION VERSUS DKK 848 MILLION YEAR AGO

May 09 2017

BRIEF-ALK-Abello: Torii submits paediatric registration application for house dust mite SLIT-tablet in Japan

* ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan

Mar 24 2017

BRIEF-ALK-Abello: FDA approval for HDM sublingual allergy immunotherapy tablet

* Said on Wednesday FDA approved Biologics License Application (BLA) for ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet (ACARIZAX in Europe)

Mar 02 2017

BRIEF-Alk submits registration application for ragweed SLIT-tablet in Europe

* Alk submits registration application for ragweed SLIT-tablet in Europe

Feb 16 2017

BRIEF-Alk Abello Q4 EBITDA ex-items slightly down at DKK 121 million

* Q4 total revenue 754 million Danish crowns ($108.49 million) versus 687 million crowns year ago

Feb 07 2017

More From Around the Web

Earnings vs. Estimates